Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.55 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.55 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16468567 | 1.00 | POLG (0.61) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL21011368 | 0.88 | POLG (0.67) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL25631339 | 0.88 | POLG (0.67) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL1333569 | 0.88 | POLG (0.67) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL25457105 | 0.87 | POLG (0.60) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL27102637 | 0.87 | POLG (0.66) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL24370820 | 0.87 | POLG (0.66) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL15343924 | 0.86 | POLG (0.61) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL432220 | 0.86 | POLG (0.61) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL18179803 | 0.86 | POLG (0.61) | POLGPOLBP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3842532-A1 | METHOD OF AMPLIFYING MRNAS AND FOR PREPARING FULL LENGTH MRNA LIBRARIES | baseclick GmbH (DE) | 2021-06-30 | — | — | EP | disclosed |
| US-10995363-B2 | Nucleotide analogs | ABBOTT MOLECULAR INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200157606-A1 | NUCLEOTIDE ANALOGS | ABBOTT MOLECULAR INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10995363-B2 | Nucleotide analogs | NUDT1, NT5C3B, RNGTT | POLG 152/4885POLB 32/4885P2RY2 314/4885 |
| US-20200157606-A1 | NUCLEOTIDE ANALOGS | NUDT1, NT5C3B, RNGTT | POLG 152/4885POLB 32/4885P2RY2 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.